Davis Polk advised underwriters represented by Citigroup Global Markets Inc., J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated in connection with the offering of $2.5 billion aggregate principal amount of notes issued by Merck & Co., Inc. The offering consisted of $1 billion principal amount of 1.1% notes due 2018, $1 billion principal amount of 2.4% notes due 2022 and $500 million principal amount of 3.6% notes due 2042.
Merck is a global health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
The Davis Polk corporate team included partner Alan Dean and associates Ryan G. Mitteness and Vanessa K. Rakel. The tax team included partner Po Sit and associate Patrick E. Sigmon. The environmental team included counsel Loyti Cheng and associate Kevin J. Klesh. The intellectual property team consisted of associates Randy Samson and Bruce Rose-Innes. Kristyn M. Dunleavy was the legal assistant on the transaction. All members of the Davis Polk team are based in the New York office.
